Core Viewpoint - Actuate Therapeutics, Inc. plans to conduct an underwritten public offering of its common stock to raise funds for working capital and general corporate purposes [1][2]. Company Overview - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1][5]. - The company's lead investigational drug, elraglusib, targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments, potentially enhancing anti-tumor immunity [5]. Offering Details - The company intends to offer shares of its common stock and may grant underwriters a 30-day option to purchase an additional 15% of the shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding the completion, size, or terms of the offering [1][6]. - The offering will be made under a shelf registration statement previously filed with the SEC, and a preliminary prospectus supplement has been filed [3].
Actuate Therapeutics Announces Proposed Public Offering of Common Stock